RTW Investments’s Orchestra BioMed OBIO Stock Holding History

RTW Investments’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.2M	Buy	9,556,063 +1,250,000	+15%	+$5.11M	0.35%	50
2026 Q1	$35.3M	Hold	8,306,063	–	–	0.35%	49
2025 Q4	$34.5M	Hold	8,306,063	–	–	0.35%	55
2025 Q3	$20.6M	Buy	8,306,063 +1	+0%	+$3	0.25%	55
2025 Q2	$22.3M	Buy	8,306,062 +99,900	+1%	+$292K	0.32%	46
2025 Q1	$35.1M	Hold	8,206,162	–	–	0.54%	35
2024 Q4	$32.8M	Buy	8,206,162 +3	+0%	+$16	0.5%	39
2024 Q3	$42.2M	Buy	8,206,159 +2,585,519	+46%	+$16.9M	0.61%	38
2024 Q2	$45.8M	Hold	5,620,640	–	–	0.71%	34
2024 Q1	$29.6M	Hold	5,620,640	–	–	0.44%	46
2023 Q4	$51.3M	Hold	5,620,640	–	–	0.8%	33
2023 Q3	$49M	Hold	5,620,640	–	–	1.03%	25
2023 Q2	$39.3M	Buy	5,620,640 +502,133	+10%	+$7.62M	0.75%	30
2023 Q1	$100M	Buy	5,118,507 +4,118,507	+412%	+$47.7M	2.09%	18
2022 Q4	$9.98M	Hold	1,000,000	–	–	0.2%	47
2022 Q3	$9.9M	Buy	+1,000,000	New	+$9.91M	0.23%	55

Other funds holding OBIO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

RTW Investments's OBIO Position: Q2 2026 in Review

RTW Investments increased its Orchestra BioMed (OBIO) stake by 15% in Q2 2026, buying an estimated $5.11M and bringing the position to 9,556,063 shares worth $41.2M. The position accounts for 0.35% of the portfolio, ranked #50.

RTW Investments first reported a position in OBIO in Q3 2022 and has held it in 16 quarters since. The position peaked at $100M in Q1 2023. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

RTW Investments held 9,556,063 shares of Orchestra BioMed worth $41.2M as of Q2 2026.
RTW Investments bought 1,250,000 Orchestra BioMed shares in Q2 2026, an estimated $5.11M.
Orchestra BioMed made up 0.35% of RTW Investments's portfolio in Q2 2026, its #50 holding.
RTW Investments first reported a position in Orchestra BioMed in Q3 2022 and has held it in 16 quarters since.
RTW Investments's Orchestra BioMed position peaked at $100M in Q1 2023.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.